CN115120655A - Piperine composition for protecting gastric mucosa and preparation method and application thereof - Google Patents
Piperine composition for protecting gastric mucosa and preparation method and application thereof Download PDFInfo
- Publication number
- CN115120655A CN115120655A CN202210937823.1A CN202210937823A CN115120655A CN 115120655 A CN115120655 A CN 115120655A CN 202210937823 A CN202210937823 A CN 202210937823A CN 115120655 A CN115120655 A CN 115120655A
- Authority
- CN
- China
- Prior art keywords
- piperine
- purified product
- composition
- gastric mucosa
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 title claims abstract description 81
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 title claims abstract description 81
- 229940075559 piperine Drugs 0.000 title claims abstract description 81
- 235000019100 piperine Nutrition 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 210000001156 gastric mucosa Anatomy 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000012264 purified product Substances 0.000 claims abstract description 85
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 36
- 229930003944 flavone Natural products 0.000 claims abstract description 36
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 36
- 235000011949 flavones Nutrition 0.000 claims abstract description 36
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 36
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 36
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241001154765 Mallotus oblongifolius Species 0.000 claims abstract description 23
- 241000271309 Aquilaria crassna Species 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 230000006378 damage Effects 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- 229930184510 Mallotus Natural products 0.000 claims description 10
- 241001060384 Mallotus <angiosperm> Species 0.000 claims description 10
- 241001122767 Theaceae Species 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 238000011068 loading method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- DSRKIBHIKLYUOK-UHFFFAOYSA-N sinensine Natural products Cc1cnc(c2cc(O)cc(O)c2)c3C(O)CCc13 DSRKIBHIKLYUOK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000007965 phenolic acids Chemical class 0.000 claims description 2
- 235000009048 phenolic acids Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 241000288049 Perdix perdix Species 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a piperine composition for protecting gastric mucosa and a preparation method and application thereof, wherein the piperine composition comprises the following components in parts by weight: 30-40 parts of piperine purified product, 25-35 parts of Mallotus oblongifolius polyphenol purified product and 20-30 parts of eaglewood leaf flavone purified product. The piperine composition provided by the invention fully exerts the biological activity of natural active ingredients, has the characteristics of synergistic effect, multiple action targets and the like, and can effectively play a role in protecting gastric mucosa by relieving oxidation reaction, relieving inflammatory reaction, inhibiting apoptosis and promoting intestinal regulation. The piperine composition has the advantages of oxidation resistance, inflammation resistance, immunity enhancement, small toxic and side effects and the like, and raw materials used in the composition are cheap and easy to obtain, and the production cost is low.
Description
Technical Field
The invention relates to the field of functional foods, in particular to a piperine composition for protecting gastric mucosa and a preparation method and application thereof.
Background
The stomach is an important digestive and absorptive organ of the human body, and food can be fully ground by the stomach and uniformly mixed with gastric acid to form pasty chyme for the absorption of the small intestine. Although the gastric mucosa can protect the stomach from being damaged, it is very vulnerable to diet, drugs, alcohol, bad mood, etc. Gastric mucosal injury is a common and frequently occurring disease worldwide, with almost all suffering from it throughout life. More potent injury factors that increase the probability of gastric mucosal ulceration include helicobacter pylori, nonsteroidal anti-inflammatory drugs, stress, steroids and ethanol. Gastric ulcer is a common disease of digestive system, and has long course of disease and easy recurrence. There are many factors inducing gastric mucosa damage, and ethanol is one of the causes of gastric mucosa damage. The cause of gastric mucosal damage is due to an imbalance between factors of gastric mucosal damage and defense factors, such as: epidermal growth factor, cell regeneration, secretion of pepsin and prostaglandins.
The key means for protecting gastric mucosa is to inhibit gastric acid and helicobacter pylori, the main drugs are basic antacids, proton pump inhibitors, H2 receptor antagonists, gastric mucosa protective agents and the like, and although the drugs have better treatment effect, the drugs have side effects in different degrees in treatment effect, such as: anaphylaxis, arrhythmia, hematopoietic hazard, etc. Therefore, it is important to find a safer and more effective gastric mucosa protective agent.
The active substances in the natural products are utilized to prevent the damage of the ethanol type gastric mucosa, and the method has the characteristics of multiple ways, multiple targets, high safety and the like. In recent years, the screening of active ingredients from natural products for the prevention of gastric mucosal damage has been the focus of research. Agricultural products are considered as natural treasures of 'natural products', active ingredients are found from food raw materials, and the method has the unique advantage of effectively and safely preventing gastric mucosa from being damaged.
Disclosure of Invention
In order to overcome the defects in the prior art, the embodiment of the invention provides a piperine composition for protecting gastric mucosa and a preparation method and application thereof.
The invention discloses: a piperine composition for protecting gastric mucosa comprises, by weight, 30-40 parts of piperine purified product, 25-35 parts of Mallotus oblongifolius polyphenol purified product and 20-30 parts of sinensine flavone purified product.
Preferably, the active ingredients of the composition include alkaloids, phenolic acids and flavonoids.
Preferably, the purity of the piperine purified product is 75-90%, the purity of the mallotus oblongifolius polyphenol purified product is 50-65%, and the purity of the eaglewood flavone purified product is 50-65%.
The invention also discloses: the preparation method of the piperine composition comprises the steps of spray drying the piperine purified product, the partridge tea polyphenol purified product and the sinensine flavone purified product, and then uniformly mixing according to the proportion.
Preferably, the purified product of piperine is prepared by pulverizing fructus Piperis, sieving with 40-60 mesh sieve, extracting with 20-30 times of 70% -80% food grade alcohol at 55-60 deg.C for 50-60 min. Loading 2.0-3.0 mg/mL piperine extract on column with HPD22 resin at flow rate of 1.5-2.0 mL/min, eluting with 80% -90% food grade alcohol at flow rate of 2.0-3.0 mg/mL, concentrating, drying, and recrystallizing for 2 times to obtain piperine purified product. The preparation method of the Mallotus furetianus polyphenol purified product comprises the steps of crushing Mallotus furetianus, sieving with a 40-60-mesh sieve, leaching with 20-30 times of 50-60% food grade alcohol at the temperature of 55-60 ℃ for 1.5-2.5 h, filtering, concentrating and drying to obtain the Mallotus furetianus polyphenol extract. Then, 5.0-6.0 mg/mL Mallotus oblongifolius polyphenol extract is loaded on a column by NKA-9 resin at the flow rate of 1.5-2.0 mL/min, and is eluted by 65% -75% of food-grade alcohol at the flow rate of 1.5-2.5 mg/mL, and the Mallotus oblongifolius polyphenol purified product is obtained after concentration and drying. The preparation method of the agilawood leaf flavone purified product comprises the steps of crushing agilawood leaves, sieving the agilawood leaves with a 40-60-mesh sieve, leaching the agilawood leaves with 15-25 times of 55-65% food-grade alcohol for 2.5-3.0 h at the temperature of 55-65 ℃, filtering, concentrating and drying to obtain the agilawood leaf flavone extract. Then, loading 4.5-5.5 mg/mL eaglewood leaf flavone extract on a column by NKA-9 resin at the speed of 1.5-2.0 mL/min, eluting with 65% -75% food-grade alcohol at the speed of 2.0-3.0 mg/mL, concentrating, and drying to obtain the eaglewood leaf flavone purified product.
The invention also discloses: a preparation for protecting gastric mucosa comprises the piperine composition and food acceptable adjuvants.
Preferably, the preparation is a tablet, a capsule, a pill or granules.
The invention also discloses: the piperine composition is used for preventing gastric mucosa injury.
The invention has the following beneficial effects: the piperine composition provided by the application fully exerts the biological activity of natural active ingredients, has the characteristics of synergistic effect, multiple action targets and the like, and can effectively play a role in protecting gastric mucosa by relieving oxidation reaction, relieving inflammatory reaction, inhibiting apoptosis and promoting intestinal regulation. The piperine composition has the advantages of oxidation resistance, inflammation resistance, immunity enhancement, small toxic and side effects and the like, and raw materials used in the composition are cheap and easy to obtain, and the production cost is low.
In order to make the aforementioned and other objects, features and advantages of the invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a graph showing the effects of piperine on ethanol-induced damage to rat gastric mucosa.
FIG. 2 is a table of different levels of piperine composition.
FIG. 3 is a table showing the results of different amounts of piperine composition on the ulcer area and inhibition rate of rat gastric mucosa.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
The invention provides a piperine composition for protecting gastric mucosa, which is prepared by the following steps:
preparation of purified piperine: pulverizing fructus Piperis, sieving with 40-60 mesh sieve, extracting with 20-30 times of 70-80% food grade alcohol at 55-60 deg.C for 50-60 min to obtain piperine. Loading 2.0-3.0 mg/mL piperine extract into column with HPD22 resin at flow rate of 1.5-2.0 mL/min, eluting with 80% -90% food grade alcohol at flow rate of 2.0-3.0 mg/mL, concentrating, drying, and recrystallizing for 2 times to obtain piperine purified product.
Preparing a mallotus oblongifolius polyphenol purified product: pulverizing Mallotus furetianus, sieving with 40-60 mesh sieve, extracting with 20-30 times of 50-60% food grade alcohol at 55-60 deg.C for 1.5-2.5 h, filtering, rotary evaporating at 55-60 deg.C for concentrating, and drying to obtain Mallotus furetianus polyphenol extract. Then, 5.0-6.0 mg/mL Mallotus oblongifolius polyphenol extract is loaded on a column by NKA-9 resin at the flow rate of 1.5-2.0 mL/min, and is eluted by 65% -75% of food-grade alcohol at the flow rate of 1.5-2.5 mg/mL, and the Mallotus oblongifolius polyphenol purified product is obtained after concentration and drying.
Preparation of the linaloe flavone purified product: pulverizing folium Neocinnamomi Delavayi, sieving with 40-60 mesh sieve, extracting with 15-25 times of 55-65% food grade alcohol at 55-65 deg.C for 2.5-3.0 h, filtering, concentrating, and drying to obtain folium Neocinnamomi Delavayi flavone extract. Then, loading 4.5-5.5 mg/mL of the sinkiang rose leaf flavone extracting solution on a column by adopting NKA-9 resin at the speed of 1.5-2.0 mL/min, eluting by using 65% -75% food-grade alcohol at the speed of 2.0-3.0 mg/mL, concentrating and drying to obtain the sinkiang rose leaf flavone purified product.
Mixing the obtained piperine purified product, Mallotus furetianus tea polyphenols purified product and Aquilaria sinensis flavone purified product at a certain proportion, and making into piperine composition.
Example 1
This example provides a piperine composition for the protection of gastric mucosa, consisting of: 30 parts of piperine purified product, 25 parts of mallotus oblongifolius polyphenol purified product and 20 parts of agilawood leaf flavone purified product.
Example 2
This example provides a piperine composition for the protection of gastric mucosa, consisting of: 30 parts of piperine purified product, 30 parts of mallotus oblongifolius purified product and 25 parts of agilawood leaf flavone purified product.
Example 3
This example provides a piperine composition for the protection of gastric mucosa, consisting of: 35 parts of piperine purified product, 25 parts of Mallotus oblongifolius polyphenol purified product and 25 parts of agilawood leaf flavone purified product
Example 4
This example provides a piperine composition for protecting gastric mucosa, consisting of: 35 parts of piperine purified product, 30 parts of mallotus oblongifolius polyphenol purified product and 25 parts of agilawood leaf flavone purified product.
Example 5
This example provides a piperine composition for the protection of gastric mucosa, consisting of: 40 parts of piperine purified product, 35 parts of mallotus oblongifolius polyphenol purified product and 30 parts of agilawood leaf flavone purified product.
Comparative example 1
The embodiment provides a piperine composition for protecting gastric mucosa, which consists of the following components: 35 parts of piperine purified product and 30 parts of mallotus oblongifolius polyphenol purified product.
Comparative example 2
The present comparative example provides a piperine composition for the protection of gastric mucosa, consisting of the following components: 35 parts of piperine purified product and 25 parts of agilawood leaf flavone purified product.
Comparative example 3
The present comparative example provides a piperine composition for the protection of gastric mucosa, consisting of the following components: 30 parts of mallotus oblongifolius polyphenol purified product and 25 parts of agilawood leaf flavone purified product.
First, experiment method
1. Molding: after 7 days of acclimation period in SPF scale laboratory, rats in blank and injured groups were administered intragastric 5% Tween-8; experimental groups the compositions prepared in the example 1-5 and the comparative example 1-3 are infused in the dosage of 80 mg/kg and b.w, the test object is continuously infused in the stomach for 7 days, after the last time of the infusion, the patient is fasted and does not prohibit water for 24 hours, then, except the normal group, the other ingredients are infused in the stomach for 4 mL/kg of absolute ethyl alcohol for modeling, and blood is taken out for dissection after 4 hours of modeling. The anterior abdominal wall between the xiphoid process and the anus is incised along the median line of the abdomen, and the stomach is removed. After the stomach tissue is unfolded, the damage condition of the stomach mucosa is observed by naked eyes, and the length and the width of the bleeding damaged part are measured by an electronic caliper. After photographing, the area (UA) (mm) of the gastric mucosa ulcer part is measured by Image J software 2 ). Ulcer index: ulcer index (%) = total area of gastric ulcer/total area of glandular stomach corresponding to gastric tissue × 100%; ulcer inhibition rate: inhibition (%) =100% -gastric tissue ulcer index of administration group/gastric tissue ulcer index of model group × 100%. Portions of the stomach tissue (0.5 cm. times.0.5 cm) were excised and immersed in 10% formalin for histopathological evaluation.
The piperine compositions with different contents are shown in figure 2, and the experiment results of the piperine compositions with different contents on the ulcer area and the inhibition rate of the rat gastric mucosa are shown in figure 3.
As can be seen from fig. 1 and 3:
(1) compared with the experimental groups 1 and 4, under the condition that the weight parts of the piperine purified product, the partridge tea polyphenol purified product and the agilawood leaf flavone purified product are reduced, the ulcer area is obviously increased, and the inhibition rate is obviously reduced, so that the weight parts of the piperine purified product, the partridge tea purified product and the agilawood leaf flavone purified product are reduced, and the effect of preventing gastric mucosa injury by using the piperine composition is not exerted.
(2) Compared with experimental groups 2 and 4, the important fraction of the piperine purified substance is reduced, and under the condition that the weight parts of the mallotus oblongifolius polyphenol purified substance and the sinapsis leaf flavone are not changed, the ulcer area is obviously increased, the inhibition rate is obviously reduced, and the reduction of the weight parts of the piperine purified substance is not beneficial to the exertion of the effect of the piperine composition on preventing gastric mucosa injury.
(3) Compared with experimental groups 3 and 4, the weight parts of the mallotus oblongifolius polyphenol purified product and the agilawood leaf flavone purified product are reduced, and under the condition that the mass fraction of the piperine purified product is not changed, the ulcer area is increased, the inhibition rate is reduced, so that the weight parts of the mallotus oblongifolius polyphenol purified product and the agilawood leaf flavone purified product are reduced, and the effect of preventing gastric mucosa injury by the piperine composition is not exerted favorably.
(4) The experimental groups 4 and 5 are compared, the increase of the parts by weight of the piperine purifyer, the partridge tea polyphenol purifyer and the eaglewood flavone purified product increases the ulcer area, and the inhibition rate decreases, so that the increase of the parts by weight of the piperine purifyer, the partridge tea polyphenol purifyer and the eaglewood flavone purified product is not beneficial to the exertion of the effect of the piperine composition on preventing gastric mucosa injury.
(5) Compared with the comparative groups 1,2 and 3, the experimental groups 1,2,3, 4 and 5 have the advantages that the loss of any one component of the piperine purified product, the mallotus oblongifolius polyphenol purified product and the linaloflavone purified product is not beneficial to the exertion of the effect of the piperine composition on preventing gastric mucosa injury. Wherein, the lack of the piperine purified product is most harmful to the exertion of the effect of the piperine composition on preventing gastric mucosa injury, and the influence of the partridge tea polyphenol purified product is inferior.
According to the conclusions (1) - (5), the piperine composition has the best effect by proportioning 35 parts of the piperine purified product, 30 parts of the partridge tea polyphenol purified product and 25 parts of the sinergic leaf flavone purified product in parts by weight, and the piperine composition is not beneficial to the composition to play a role in preventing gastric mucosa injury by increasing or reducing or deleting the components of the piperine purified product, the partridge tea polyphenol purified product and the sinergic leaf flavone purified product.
The principle and the implementation mode of the invention are explained by applying specific embodiments in the invention, and the description of the embodiments is only used for helping to understand the method and the core idea of the invention; meanwhile, for a person skilled in the art, according to the idea of the present invention, the specific embodiments and the application range may be changed, and in summary, the content of the present specification should not be construed as a limitation to the present invention.
Claims (8)
1. A piperine composition for protecting gastric mucosa is characterized by comprising, by weight, 30-40 parts of piperine purified product, 25-35 parts of mallotus oblongifolius polyphenol purified product and 20-30 parts of sinensine flavone purified product.
2. The composition of piperine for the protection of the gastric mucosa of claim 1, wherein: the active ingredients of the composition comprise alkaloids, phenolic acids and flavonoids.
3. The composition of piperine for the protection of the gastric mucosa of claim 1, wherein: the purity of the piperine purified product is 75-90%, the purity of the Mallotus furetianus tea polyphenol purified product is 50-65%, and the purity of the agilawood leaf flavone purified product is 50-65%.
4. A process for the preparation of the piperine composition of any one of claims 1 to 3, comprising: spray drying the piperine purified product, the Mallotus oblongifolius polyphenol purified product and the agaric flavone purified product, and then uniformly mixing according to the proportion.
5. A process for preparing a piperine composition according to claim 4, wherein: the purified product of piperine is prepared by pulverizing fructus Piperis, sieving with 40-60 mesh sieve, extracting with 20-30 times of 70-80% food grade alcohol at 55-60 deg.C for 50-60 min, concentrating, and drying to obtain piperine extract; then, loading 2.0-3.0 mg/mL piperine extract into column at flow rate of 1.5-2.0 mL/min by HPD22 resin, eluting with 80% -90% food grade alcohol at flow rate of 2.0-3.0 mg/mL, concentrating, drying, and recrystallizing for 2 times to obtain piperine purified product; the preparation method of the Mallotus furetianus polyphenol purified product comprises the steps of crushing Mallotus furetianus, sieving with a 40-60-mesh sieve, leaching with 20-30 times of 50-60% food grade alcohol at the temperature of 55-60 ℃ for 1.5-2.5 h, filtering, concentrating and drying to obtain Mallotus furetianus polyphenol extract; then, loading 5.0-6.0 mg/mL Mallotus oblongifolius polyphenol extract on a column at the flow rate of 1.5-2.0 mL/min by using NKA-9 resin, eluting with 65-75% food-grade alcohol at the flow rate of 1.5-2.5 mg/mL, concentrating and drying to obtain the purified Mallotus oblongifolius polyphenol; the preparation method of the agilawood leaf flavone purified product comprises the steps of crushing agilawood leaves, sieving the crushed agilawood leaves with a 40-60-mesh sieve, leaching the agilawood leaves for 2.5-3.0 hours by using 15-25 times of 55-65% food-grade alcohol at the temperature of 55-65 ℃, and filtering, concentrating and drying the extract to obtain an agilawood leaf flavone extract; then, loading 4.5-5.5 mg/mL eaglewood leaf flavone extract on a column by NKA-9 resin at the speed of 1.5-2.0 mL/min, eluting with 65% -75% food-grade alcohol at the speed of 2.0-3.0 mg/mL, concentrating, and drying to obtain the eaglewood leaf flavone purified product.
6. A formulation for protecting the gastric mucosa, characterized in that: comprising the piperine composition of any one of claims 1 to 3 and a food acceptable adjuvant.
7. The formulation for protecting gastric mucosa according to claim 6, wherein: the preparation is tablet, capsule, pill or granule.
8. Use of the piperine composition of any one of claims 1 to 3 for preventing damage to the gastric mucosa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210937823.1A CN115120655A (en) | 2022-08-05 | 2022-08-05 | Piperine composition for protecting gastric mucosa and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210937823.1A CN115120655A (en) | 2022-08-05 | 2022-08-05 | Piperine composition for protecting gastric mucosa and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115120655A true CN115120655A (en) | 2022-09-30 |
Family
ID=83384995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210937823.1A Pending CN115120655A (en) | 2022-08-05 | 2022-08-05 | Piperine composition for protecting gastric mucosa and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115120655A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117122060A (en) * | 2023-10-24 | 2023-11-28 | 海南省农业科学院三亚研究院(海南省实验动物研究中心) | Preparation method and application of stable piperine Pickering emulsion |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111972667A (en) * | 2020-08-31 | 2020-11-24 | 海南省农业科学院农产品加工设计研究所 | Composite agilawood leaf concentrated powder for relaxing bowel and preparation method thereof |
| CN113616744A (en) * | 2021-09-01 | 2021-11-09 | 山西大学 | Preparation method and application of millet whole grain flavone active component |
| CN114190458A (en) * | 2021-12-08 | 2022-03-18 | 海南省农业科学院农产品加工设计研究所 | Compound Mallotus oblongifolius tea polyphenol concentrated powder and preparation method thereof |
| CN114586976A (en) * | 2021-11-12 | 2022-06-07 | 海南省农业科学院农产品加工设计研究所 | Composite piperine concentrated powder and preparation method thereof |
-
2022
- 2022-08-05 CN CN202210937823.1A patent/CN115120655A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111972667A (en) * | 2020-08-31 | 2020-11-24 | 海南省农业科学院农产品加工设计研究所 | Composite agilawood leaf concentrated powder for relaxing bowel and preparation method thereof |
| CN113616744A (en) * | 2021-09-01 | 2021-11-09 | 山西大学 | Preparation method and application of millet whole grain flavone active component |
| CN114586976A (en) * | 2021-11-12 | 2022-06-07 | 海南省农业科学院农产品加工设计研究所 | Composite piperine concentrated powder and preparation method thereof |
| CN114190458A (en) * | 2021-12-08 | 2022-03-18 | 海南省农业科学院农产品加工设计研究所 | Compound Mallotus oblongifolius tea polyphenol concentrated powder and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曾昭龙主编: "《实用临床中药学》", 30 June 2020, 河南科学技术出版社 * |
| 石风祥等: "沉砂汤治疗呃逆", 《中国临床医生》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117122060A (en) * | 2023-10-24 | 2023-11-28 | 海南省农业科学院三亚研究院(海南省实验动物研究中心) | Preparation method and application of stable piperine Pickering emulsion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al Snafi | Pharmacological and therapeutic importance of a review | |
| Das et al. | Okra and its various applications in drug delivery, food technology, health care and pharmacological aspects-a review | |
| Priya et al. | Phyllanthus emblica Linn.(Amla)—a natural gift to humans: an overview | |
| Al-Snafi | Chemical constituents and pharmacological effects of Lithospermum officinale | |
| KR102121153B1 (en) | Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof | |
| US20050287235A1 (en) | Antiulcer herbal compositions | |
| CN104351610B (en) | A kind of health care oral liquid and preparation method for inhibiting alcohol absorption, promoting alcohol metabolism | |
| CN115120655A (en) | Piperine composition for protecting gastric mucosa and preparation method and application thereof | |
| CN101926818A (en) | Medicine composition containing tea polyphenol and alginic acid and application thereof | |
| Missoun et al. | Antidiabetic bioactive compounds from plants | |
| CN109498549A (en) | A kind of ozone oil compound hemorrhoidal cream and preparation method thereof | |
| CN103007000A (en) | New medicine for treating burns and wounds and preparation method thereof | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN106421075A (en) | Preparation method and application of anti-oxidation active component of bamboo willows | |
| KR101478196B1 (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of Cudrania tricuspidata as a main component | |
| CN101972284B (en) | Preparation method of pine needle fat soluble extract and application thereof in preparing drug for treating gastric ulcer | |
| Bhatt et al. | Medicinal Importance of Tinospora Herbs (Tinospora cordifolia) | |
| Tantra et al. | Alpha-mangostin as potent osteogenesis and anti-inflammation bioactive material-literature review | |
| Nyeem et al. | Cassia fistula (Bundaralati) Linn: Phytochemical and pharmacological studies: A review | |
| CN101347608A (en) | Chinese medicine soft capsules with cholagogic efficacy and preparation method thereof | |
| KR20100062585A (en) | Pharmaceutical composition for the treatment or prevention of obesity comprising the extract from myristica fragrans houttuyn | |
| JP2003104901A (en) | Composition for health promotion | |
| RU2288735C2 (en) | Agent, method for its preparing and method for prophylaxis and treatment of small pelvis organs inflammatory disease and rectum disease | |
| WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
| KR20120090123A (en) | Composition of film forming solution for alleviation of menstrual cramp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220930 |
|
| RJ01 | Rejection of invention patent application after publication |